Mankind Pharma is set to list on May 9 with a premium of Rs 120 apiece according to grey market trends. The company is valued at a price-to-earnings ratio of 30 times FY22 earnings and has a market capitalisation of Rs 44,000 crore. The initial share sale of the company was subscribed 15.32 times with strong interest from QIBs and is the largest IPO so far this year. The company has 25 manufacturing facilities across India, a dedicated in-house R&D centre and a team of over 600 scientists.
Proxy companies bat for ‘new’ vote on promoter pay
Proxy advisory firms urge regulators to implement a majority-of-minority voting mechanism for approving promoter remuneration, citing significant increases in payouts to promoters and conflicts of
January 16, 2025